16 completed, 3 unknown, 2 not yet recruiting, 1 terminated. 11 Phase 2, 9 Phase 1, 5 Phase 3, 1 Not applicable.
Follow Jaktinib: new trials by email Literature Review of Jaktinib trials Research Report on Jaktinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease Jaktinib - Acute Graft vs Host Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 49 | 2026-10-10 | 2026-10-21 |
| Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis Gecacitinib - aGVHD Prophylaxis | Not applicable | Not yet recruiting | Nanfang Hospital, Southern Medical University | 40 | 2026-03-01 | 2026-02-27 |
| A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Jaktinib Hydrochloride Tablets - Acute Graft-Versus-Host Disease | Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 60 | 2024-12-01 | 2024-03-06 |
| A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants Jaktinib, Placebo - Healthy Participants | Phase 1 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 32 | 2024-03-19 | 2024-12-12 |
| Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions Jaktinib Hydrochloride Tablets - Myelofibrosis | Phase 1 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 52 | 2023-11-29 | 2024-01-11 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) Jaktinib - Ankylosing Spondylitis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 207 | 2023-11-10 | 2026-09-24 |
| Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) Jaktinib, Placebo - Ankylosing Spondylitis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 265 | 2023-07-20 | 2026-09-22 |
| Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia. Jaktinib, Placebo - COVID-19 Pneumonia | Phase 2 | Unknown | First Affiliated Hospital of Zhejiang University | 60 | 2023-03-01 | 2023-01-17 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Jaktinib - Alopecia Areata | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 315 | 2022-03-25 | 2025-03-18 |
| A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers Jaktinib Hydrochloride Tablets, Itraconazole capsule, Rifampicin Capsules - Healthy Volunteers | Phase 1 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 40 | 2021-10-27 | 2024-02-07 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Jaktinib, azacitidine - Myelodysplastic Syndromes, Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 1 | 2021-09-30 | 2022-12-01 |
| Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Jaktinib, placebo - Alopecia Areata | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 425 | 2021-09-04 | 2025-03-14 |
| Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function Jaktinib Hydrochloride Tablets - Hepatic Insufficiency, Healthy Subjects | Phase 1 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 24 | 2021-08-27 | 2024-01-11 |
| A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis Jaktinib, Placebo - Moderate-to-Severe Plaque Psoriasis | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 123 | 2021-03-11 | 2025-02-20 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets - Myelofibrosis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 105 | 2021-02-05 | 2023-11-13 |
| Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis Jaktinib, placebo - Atopic Dermatitis | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 166 | 2020-12-02 | 2023-03-24 |
| Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis Jaktinib Hydrochloride Tablets, Placebo - Ankylosing Spondylitis | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 108 | 2020-12-01 | 2023-03-29 |
| Jaktinib Hydrochloride Cream For Atopic Dermatitis Jaktinib Hydrochloride Cream, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 107 | 2020-10-14 | 2024-04-02 |
| Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Jaktinib Hydrochloride Tablets, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 91 | 2020-09-08 | 2024-12-12 |
| A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata Jaktinib hydrochloride cream, Placebo - Alopecia Areata(AA) | Phase 1 / Phase 2 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 160 | 2020-08-12 | 2024-03-06 |
Showing 20 of 22. Sign in to see all of them.
Primary Myelofibrosis (5) · Alopecia Areata (3) · Spondylitis, Ankylosing (3) · Dermatitis, Atopic (2) · COVID-19 (1) · Hepatic Insufficiency (1) · Idiopathic Pulmonary Fibrosis (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Pneumonia (1)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (19) · Nanfang Hospital, Southern Medical University (2) · First Affiliated Hospital of Zhejiang University (1)
China (21)
Jason Wu (4) · Chunde Bao (2) · Qianjin Lu, PhD (2) · Chunde Bao, MD (1) · Jianya Zhou (1) · Jianzhong Zhang, PhD (1) · Jie Jin, MD (1) · Jie Jin, PhD (1) · LiYan Miao (1) · Liyan Miao, PhD (1) · Qianjin Lu (1) · Weifeng Zhao, PhD (1) · Xinghua Gao, PhD (1) · Yanhua Ding, MD (1) · Yongping Song, PhD (1)
PMID 32519831, PMID 38380328, PMID 39442386, PMID 39695117, PMID 39753296